Our objective was to evaluate the immunogenicity of branded and biosimilar infliximab by detecting changes in T-helper-9 (Th9) percentages induced by an in vitro stimulation test.
The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
Talotta, Rossella;Doria, Andrea
;Batticciotto, Alberto;DITTO, MARIA CHIARA;
2017
Abstract
Our objective was to evaluate the immunogenicity of branded and biosimilar infliximab by detecting changes in T-helper-9 (Th9) percentages induced by an in vitro stimulation test.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ijms-18-02127.pdf
accesso aperto
Descrizione: artilo principale
Tipologia:
Published (publisher's version)
Licenza:
Creative commons
Dimensione
2.9 MB
Formato
Adobe PDF
|
2.9 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
